Preclinical evidence indicates that prion diseases can respond favorably to passive immunotherapy. However, certain antibodies to the cellular prion protein PrPC can be toxic. Comprehensive studies of structure–function relationships have revealed that the flexible amino-terminal tail of PrPC is instrumental for mediating prion toxicity. In a first-in-human study, an anti-prion antibody has been recently administered to patients diagnosed with sporadic Creutzfeldt–Jakob's disease, the most prevalent human prion disease. Moreover, large-scale serosurveys have mapped the prevalence of naturally occurring human anti-prion autoantibodies in health and disease. Here, we provide a perspective on the limitations and opportunities of therapeutic anti-prion antibodies.
Skip Nav Destination
Article navigation
September 2020
Issue Editors
-
Cover Image
Cover Image
This issue of Emerging Topics in Life Sciences is guest edited by Richard Reece, and celebrates 10 years of the Royal Society of Biology. The cover features a photograph submitted by Claire Kremen, who's article discusses how the silvopastoral system in Colombia restores connectivity to landscapes and improves conditions for biodiversity while providing cattle farmers with improved productivity and profitability. Photograph by Andrés Felipe Zuluaga Salazar, The Nature Conservancy.
Perspective|
July 07 2020
Recent developments in antibody therapeutics against prion disease
Karl Frontzek
;
Institute of Neuropathology, University of Zurich, Zurich, Switzerland
Correspondence: Karl Frontzek ([email protected]) or Adriano Aguzzi ([email protected])
Search for other works by this author on:
Adriano Aguzzi
Institute of Neuropathology, University of Zurich, Zurich, Switzerland
Correspondence: Karl Frontzek ([email protected]) or Adriano Aguzzi ([email protected])
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
April 27 2020
Revision Received:
June 15 2020
Accepted:
June 17 2020
Online ISSN: 2397-8562
Print ISSN: 2397-8554
© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society and the Royal Society of Biology
2020
Emerg Top Life Sci (2020) 4 (2): 169–173.
Article history
Received:
April 27 2020
Revision Received:
June 15 2020
Accepted:
June 17 2020
Citation
Karl Frontzek, Adriano Aguzzi; Recent developments in antibody therapeutics against prion disease. Emerg Top Life Sci 8 September 2020; 4 (2): 169–173. doi: https://doi.org/10.1042/ETLS20200002
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.